Singularity Capital · Jun 2025
Portfolio write-up summarizing the company’s disease-focused model, founders’ backgrounds, and named investors.
A Disease Focused Biotech, Building Multiple Billion Dollar Drugs
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
San Francisco biotech founded in 2024 that is building multi-modal therapeutics for Rett syndrome and other rare diseases, using a lean, expert-led, capital-efficient approach that combines disease biology, AI, CROs, and existing modality tools to advance preclinical drug candidates.
Primary product
Multi-modal rare-disease therapeutics, starting with Rett syndrome candidates
Founded
2024
Headquarters
San Francisco, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Rare disease therapeutics
Offices
San Francisco, California, United States
Open Positions
0 jobs at Uncommon Therapeutics
No open positions
Check back later for new openings